Cipla licenses HER2 bispecific ADC TQB2102 from Sino Biopharmaceutical

The agreement gives Cipla exclusive rights to develop and commercialise the investigational HER2-targeted bispecific antibody-drug conjugate TQB2102 across India, South Africa and five additional emerging markets.

Cipla has entered into an exclusive licensing agreement with Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group for TQB2102, a bispecific antibody-drug conjugate targeting HER2.

The deal expands Cipla's oncology pipeline with a late-stage asset being investigated across multiple HER2-expressing cancers, including breast and gastric cancers.

Field	Content
Alert Type	Deal
Companies	Cipla; Sino Biopharmaceutical; Chia Tai Tianqing Pharmaceutical Group
Deal Type	Exclusive licensing agreement
Asset or Company	TQB2102
Therapy Area(s)	Oncology; HER2-expressing cancers
Technology or Modality	HER2-targeted bispecific antibody-drug conjugate
Deal Value	Financial terms were not disclosed
Development Stage	Late-stage clinical development
Geography	India, South Africa and five additional emerging markets
What Happened	Cipla entered into an exclusive licensing agreement with Chia Tai Tianqing Pharmaceutical Group, part of Sino Biopharmaceutical, covering the development and commercialisation of TQB2102 in India, South Africa and five additional emerging markets.
Why It Matters	The agreement gives Cipla access to a differentiated late-stage HER2-targeted oncology asset and strengthens its speciality oncology pipeline across important emerging markets.
Supporting Context	TQB2102 is a bispecific antibody-drug conjugate being evaluated for the treatment of multiple HER2-expressing cancers.
Strategic Rationale	The licence supports Cipla's strategy of expanding access to innovative oncology medicines while adding an advanced targeted therapy to its portfolio.
Potential Impact	If successfully developed and approved, TQB2102 could expand treatment options for patients with HER2-expressing tumours across Cipla's licensed territories.
Key Takeaway	Cipla has secured exclusive rights to a late-stage HER2 bispecific ADC across seven emerging markets, strengthening its targeted oncology portfolio.
What to Watch	Clinical development of TQB2102, subsequent regulatory filings and the programme's progression towards commercialisation in the licensed territories.
Primary Source	Cipla
Relevant Date	1 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com